PF-Atlas › Clinical Trials › NCT01203943

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis

CC-930 · Phase 2

Registry ID
NCT01203943
Phase
Phase 2
Status
Terminated
Drug / intervention
CC-930
Sponsor
Celgene
Start
2011-01-01
Enrollment
28
Locations
22

About this trial

The primary purpose of the study is to evaluate the safety and PK profile of CC-930 in idiopathic pulmonary fibrosis patients.

View NCT01203943 on ClinicalTrials.gov →

Explore related

All CC-930 trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT01203943 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.